Marketwire -- London, UK; Brentwood, TN; 9 October 2008 - Protherics PLC
("Protherics" or the "Company"), the international biopharmaceutical
company focused on critical care and cancer, in accordance with Listing
Rule 3.5.6, notifies the following details in respect of the block
listing for its Individual Unapproved share option arrangements:
